Astellas Pharma Gmbh

Medivation Prostate Therapeutics, Inc.

Kabushiki Kaisha Toshiba

Toshiro Sakai

Koji Nishimura

Shinsuke Oba

Douglas Alan Lorenz

Sanjay Konagurthu

Randy J Wald

Hiroyasu Toyota

Ryousuke Irie

Jason A Everett

Atsushi Kanbayashi

Toshiyuki Suzuki

Yuuki Takaishi

Takanari Inatomi

Ryo Kojima

Hiroshi Nakamura

Kazuhiro Watanabe

Akio Takahashi

Sheila Matz

Akira Takagi

Mikio Izumi

Yasushi Tsuboi

Masafumi Komai

Seiji Takae

Kenjiro Fukamichi

Hajime Aoki

Yuki Kasashima

Takatsune Yoshida

Katsushi Hasegawa

Makoto Kuramochi

Sachie Namiki

Yoshiaki Umemoto

Tsuyoshi Kiyota

Yurina Ansei

Ryota Azuma

Kumi Naiki

Dal Oyama

Yumiko Suda

Marina Tanaka

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Formulations of enzalutamide

Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Pharmaceutical composition for oral administration comprising enzalutamide

Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.

Pharmaceutical composition for oral administration

To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.

Pharmaceutical composition containing mirabegron

A neutron reactor includes a neutron shield which is disposed outside a nuclear reactor core and adapted to absorb neutrons leaking from the core. The neutron shield includes a plurality of containers each of which contains a powdered neutron absorbing material and which are stacked with one another in a vertical direction, and a cladding tube which houses the containers. The neutron absorbing material is composed of BC powder.

Neutron shield

A fast reactor having a reactivity control reflector has a reactor vessel in which a coolant is accommodated, a reactor core which is installed in the reactor vessel and dipped with the coolant, and a reflector installed outside of the reactor core so as to be movable in a vertical direction for controlling the reactivity of the reactor core. The reflector of the fast reactor has a lower neutron reflecting portion having a neutron reflection capability higher than that of the coolant and an upper cavity portion located above the neutron reflecting portion and having a neutron reflection capability lower than that of the coolant. The cavity portion is composed of a plurality of cylindrical hermetically-sealed vessels.

Fast reactor having reactivity control reflector

Growing community of inventors

Tokyo, Japan

Toshiro Sakai